Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/162636
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Alonso Padilla, Julio | - |
dc.contributor.author | Abril, Marcelo | - |
dc.contributor.author | Alarcón de Noya, Belkisyolé | - |
dc.contributor.author | Almeida, Igor Correia de | - |
dc.contributor.author | Angheben, Andrea | - |
dc.contributor.author | Araujo Jorge, Tania | - |
dc.contributor.author | Chatelain, Eric | - |
dc.contributor.author | Esteva, Mónica | - |
dc.contributor.author | Gascón i Brustenga, Joaquim | - |
dc.contributor.author | Grijalva, Mario J. | - |
dc.contributor.author | Guhl, Felipe | - |
dc.contributor.author | Hasslocher-Moreno, Alejandro M. | - |
dc.contributor.author | Lopez, Manuel C. | - |
dc.contributor.author | Luquetti, Alejandro | - |
dc.contributor.author | Noya, Oscar | - |
dc.contributor.author | Pinazo, Maria-Jesus | - |
dc.contributor.author | Ramsey, Janine M. | - |
dc.contributor.author | Ribeiro, Isabela | - |
dc.contributor.author | Ruiz, Andres M. | - |
dc.contributor.author | Schijman, Alejandro G. | - |
dc.contributor.author | Sosa-Estani, Sergio | - |
dc.contributor.author | Thomas, M.Carmen | - |
dc.contributor.author | Torrico, Faustino | - |
dc.contributor.author | Zrein, Maan | - |
dc.contributor.author | Picado de Puig, Albert | - |
dc.date.accessioned | 2020-05-27T17:10:56Z | - |
dc.date.available | 2020-05-27T17:10:56Z | - |
dc.date.issued | 2020-04-23 | - |
dc.identifier.issn | 1935-2735 | - |
dc.identifier.uri | http://hdl.handle.net/2445/162636 | - |
dc.description.abstract | Six to 7 million people are estimated to be infected by Trypanosoma cruzi, the parasite causing Chagas disease. Thirty to 40% of them, i.e., 1.8 to 2.4 million people, will suffer cardiac disorders and/or digestive clinical manifestations if they are not treated early during the course of the infection [1, 2]. However, only a small fraction of patients are properly diagnosed and treated [3]. Current clinical guidelines recommend treating T. cruzi–infected people if they are asymptomatic or present early symptoms of the disease (Table 1) [4, 5]. Benznidazole (BNZ) and nifurtimox (NFX) are the first-line antiparasitic treatments currently available, both with long administration regimens (60 days) that can produce adverse side effects [6–8]. Despite the fact they are not 100% effective in patients with chronic disease [9–12], they are the only drugs currently registered, and the benefits of their administration have been confirmed in several clinical studies. Currently, clinical trials with new compounds, using alternative regimens that aim to maintain efficacy whilst reducing toxicity, are ongoing and could lead to new therapeutic opportunities and/or policy change. | - |
dc.format.extent | 10 | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | PLoS | - |
dc.relation.isformatof | Reproducció del document publicat a: http://dx.doi.org/ 10.1371/journal.pntd.0008035 | - |
dc.relation.ispartof | PLoS Neglected Tropical Diseases , 2020 , vol. 14 , num.4 , p.e0008035 | - |
dc.relation.uri | http://dx.doi.org/ 10.1371/journal.pntd.0008035 | - |
dc.rights | cc by (c) Alonso-Padilla et al., 2020 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es | - |
dc.source | Articles publicats en revistes (ISGlobal) | - |
dc.subject.classification | Malaltia de Chagas | - |
dc.subject.classification | Parasitologia mèdica | - |
dc.subject.other | Chagas' disease | - |
dc.subject.other | Medical parasitology | - |
dc.title | Target product profile for a test for the early assessment of treatment efficacy in Chagas disease patients: An expert consensus. | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2020-05-22T18:01:36Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 32324735 | - |
Appears in Collections: | Articles publicats en revistes (ISGlobal) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Alonso-Padilla_J_PLoS_Negl_Trop_Dis_2020.pdf | 443.31 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License